RDF/XMLNTriplesTurtleShow queryShare
SubjectPredicateObject
http://purl.uniprot.org/citations/26340930http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/26340930http://www.w3.org/2000/01/rdf-schema#comment"Diabetic retinopathy (DR) is the leading cause of blindness in the working-age population in the U.S. The vision-threatening processes of neuroglial and vascular dysfunction in DR occur in concert, driven by hyperglycemia and propelled by a pathway of inflammation, ischemia, vasodegeneration, and breakdown of the blood retinal barrier. Currently, no therapies exist for normalizing the vasculature in DR. Here, we show that a single intravitreal dose of adeno-associated virus serotype 2 encoding a more stable, soluble, and potent form of angiopoietin 1 (AAV2.COMP-Ang1) can ameliorate the structural and functional hallmarks of DR in Ins2Akita mice, with sustained effects observed through six months. In early DR, AAV2.COMP-Ang1 restored leukocyte-endothelial interaction, retinal oxygenation, vascular density, vascular marker expression, vessel permeability, retinal thickness, inner retinal cellularity, and retinal neurophysiological response to levels comparable with nondiabetic controls. In late DR, AAV2.COMP-Ang1 enhanced the therapeutic benefit of intravitreally delivered endothelial colony-forming cells by promoting their integration into the vasculature and thereby stemming further visual decline. AAV2.COMP-Ang1 single-dose gene therapy can prevent neurovascular pathology, support vascular regeneration, and stabilize vision in DR."xsd:string
http://purl.uniprot.org/citations/26340930http://purl.org/dc/terms/identifier"doi:10.2337/db14-1030"xsd:string
http://purl.uniprot.org/citations/26340930http://purl.uniprot.org/core/author"Zhang X."xsd:string
http://purl.uniprot.org/citations/26340930http://purl.uniprot.org/core/author"Walker K."xsd:string
http://purl.uniprot.org/citations/26340930http://purl.uniprot.org/core/author"Gao G."xsd:string
http://purl.uniprot.org/citations/26340930http://purl.uniprot.org/core/author"Li D.Y."xsd:string
http://purl.uniprot.org/citations/26340930http://purl.uniprot.org/core/author"Das S.K."xsd:string
http://purl.uniprot.org/citations/26340930http://purl.uniprot.org/core/author"Koh G.Y."xsd:string
http://purl.uniprot.org/citations/26340930http://purl.uniprot.org/core/author"Uehara H."xsd:string
http://purl.uniprot.org/citations/26340930http://purl.uniprot.org/core/author"Krizaj D."xsd:string
http://purl.uniprot.org/citations/26340930http://purl.uniprot.org/core/author"Barabas P."xsd:string
http://purl.uniprot.org/citations/26340930http://purl.uniprot.org/core/author"Stitt A.W."xsd:string
http://purl.uniprot.org/citations/26340930http://purl.uniprot.org/core/author"Carroll L.S."xsd:string
http://purl.uniprot.org/citations/26340930http://purl.uniprot.org/core/author"Ambati B.K."xsd:string
http://purl.uniprot.org/citations/26340930http://purl.uniprot.org/core/author"Gibson C.C."xsd:string
http://purl.uniprot.org/citations/26340930http://purl.uniprot.org/core/author"Rai R.R."xsd:string
http://purl.uniprot.org/citations/26340930http://purl.uniprot.org/core/author"Medina R.J."xsd:string
http://purl.uniprot.org/citations/26340930http://purl.uniprot.org/core/author"Cahoon J.M."xsd:string
http://purl.uniprot.org/citations/26340930http://purl.uniprot.org/core/author"Muddana S.K."xsd:string
http://purl.uniprot.org/citations/26340930http://purl.uniprot.org/core/author"Archer B.J."xsd:string
http://purl.uniprot.org/citations/26340930http://purl.uniprot.org/core/author"Flood M.M."xsd:string
http://purl.uniprot.org/citations/26340930http://purl.uniprot.org/core/author"Messenger W.B."xsd:string
http://purl.uniprot.org/citations/26340930http://purl.uniprot.org/core/author"Nielson S."xsd:string
http://purl.uniprot.org/citations/26340930http://purl.uniprot.org/core/author"O'Neil C.L."xsd:string